Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives

Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ly, Karen, Beck, Kristen M, Smith, Mary P, Orbai, Ana-Maria, Liao, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717840/
https://www.ncbi.nlm.nih.gov/pubmed/31696051
http://dx.doi.org/10.2147/PTT.S161453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717840/
https://www.ncbi.nlm.nih.gov/pubmed/31696051
http://dx.doi.org/10.2147/PTT.S161453

Ejemplares similares